OncoGenex Pharma (OGXI) Announces Phase 2 Spruce Did Not Reach Statistical Significance
Tweet Send to a Friend
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced that data from the Phase 2 Spruce™ trial evaluating the combination of apatorsen with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
